• Explore /
  • Poster
  • / Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line (1L) treatment of <em>RAS</em> wild-type (wt) metastatic colorectal cancer (mCRC) in Germany: Data from the FIRE-3 (AIO KRK-0306) study.

Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line (1L) treatment of RAS wild-type (wt) metastatic colorectal cancer (mCRC) in Germany: Data from the FIRE-3 (AIO KRK-0306) study.

Abstract Poster

Authors

Sebastian Stintzing

Sebastian Stintzing

University Hospital, LMU Munich, Munich, Germany

Sebastian Stintzing , Ilse van Oostrum , Chris Pescott , Alma Katharina Steinbach-Buechert , Bart Heeg , Volker Heinemann

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT00433927

Citation

J Clin Oncol 36, 2018 (suppl 4S; abstr 800)

DOI

10.1200/JCO.2018.36.4_suppl.800

Abstract #

800

Poster Bd #

L23

Abstract Disclosures

Similar Posters

First Author: Ilse Van Oostrum

First Author: Madiha Naseem

First Author: Madiha Naseem

First Author: Satoshi Yuki